Shots:

• Alvotech will be responsible for the development and supply of AVT02 in selected APAC market- while DKSH will be responsible for the registration and commercialization of the therapy
• The alliance allows the Alvotech to gain access to DKHS’s commercial expertise- which will aid patients to get benefited with high-quality biosimilar therapies
• AVT02 is a biosimilar referencing AbbVie’s Humira- which is indicated to treat RA- AS- PP- PsO- UC & CD with its anticipated regulatory filing to the EMA & the US FDA in H2’20

Click here ­to­ read full press release/ article | Ref: Alvotech | Image: Contract Pharma